NCT04736173Phase 2Completed

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Study sponsor: Arcus Biosciences, Inc. · RCUS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-17Actual
Enrollment · participants169Actual
Source updated2026-10-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: May 2027. After: 17 Sep 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview